Skip to main content

Table 4 All-cause and neutropenia-related utilization by cycle

From: Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

   Total (N = 12,056) Filgrastim (N = 373) Pegfilgrastim (N = 11,683)
All-cause Hospitalizations n (%)* 620 (5.1) 38 (10.2) 582 (5.0)
Mean ± SD 0.06 ± 0.26 0.14 ± 0.46 0.05 ± 0.25
Ambulatory visits n (%)* 12,051 (100) 373 (100) 11,678 (100)
Mean ± SD 5.5 ± 3.7 9.5 ± 5.9 5.4 ± 3.5
Emergency room visits n (%)* 943 (7.8) 27 (7.2) 916 (7.8)
Mean ± SD 0.11 ± 0.46 0.09 ± 0.32 0.11 ± 0.46
Neutropenia- related Hospitalizations n (%)* 73 (0.61) 5 (1.34) 68 (0.58)
Mean ± SD 0.01 ± 0.08 0.02 ± 0.17 0.01 ± 0.08
Ambulatory visits n (%)* 3,422 (28.4) 148 (39.7) 3,274 (28.0)
Mean ± SD 0.42 ± 0.93 2.1 ± 3.3 0.36 ± 0.68
Emergency room visits n (%)* 32 (0.27) 1 (0.27) 31 (0.27)
Mean ± SD 0.00 ± 0.05 0.00 ± 0.05 0.00 ± 0.05
  1. * Number of cycles with the event and percentage of those cycles among all cycles.
  2. Mean and standard deviation of the number of events per cycle.